Related Experiment Videos
Vitamin A eyedrops for superior limbic keratoconjunctivitis
Y Ohashi1, H Watanabe, S Kinoshita
1Division of Ophthalmology, Kansai Rosai Hospital, Hyogo, Japan.
American Journal of Ophthalmology
|May 15, 1988
Summary
Topical vitamin A (retinol palmitate) eyedrops effectively treated superior limbic keratoconjunctivitis in 83% of patients. Lesions remained resolved with continued treatment, indicating a promising therapeutic option for this eye condition.
Area of Science:
- Ophthalmology
- Dermatology
- Retinoid Research
Background:
- Superior limbic keratoconjunctivitis (SLK) is a chronic inflammatory eye condition.
- Current treatments for SLK can have limited efficacy or side effects.
- The role of vitamin A in ocular surface health is well-established.
Observation:
- A study involved 12 patients diagnosed with superior limbic keratoconjunctivitis.
- Patients received treatment with topical vitamin A (retinol palmitate) eyedrops.
- A minimum follow-up period of three months was maintained for all participants.
Findings:
- Topical vitamin A eyedrops demonstrated significant efficacy in treating SLK.
- Eighty-three percent (10 out of 12) of patients showed improvement to varying degrees.
- Continued application of vitamin A eyedrops prevented recurrence of SLK lesions.
Implications:
- Topical vitamin A (retinol palmitate) offers a potentially effective and well-tolerated treatment for superior limbic keratoconjunctivitis.
- This finding suggests vitamin A supplementation may be a valuable therapeutic strategy for managing SLK.
- Further research could explore optimal dosages and long-term outcomes of vitamin A therapy for ocular surface diseases.